Dexamethasone

證據等級: L5

預測適應症: 10 個

Dexamethasone: From Inflammatory & Autoimmune Conditions to Alopecia Areata

One-Sentence Summary

Dexamethasone is a potent synthetic glucocorticoid widely used as an anti-inflammatory and immunosuppressive agent across a broad range of clinical conditions — from allergic reactions and autoimmune diseases to supportive care in oncology — though no Singapore HSA registration is currently on file. The TxGNN model predicts it may be effective for Alopecia Areata (AA), with no directly relevant registered clinical trials but 20 publications (including 1 RCT and multiple prospective cohorts) specifically examining Dexamethasone in AA treatment.

Quick Overview

Item	Content
Original Indication	Anti-inflammatory and immunosuppressive therapy (no Singapore HSA registration on file)
Predicted New Indication	Alopecia Areata
TxGNN Prediction Score	99.99%
Evidence Level	L2
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the current structured record. Based on well-established pharmacology, Dexamethasone is a synthetic glucocorticoid that binds the glucocorticoid receptor (GR-α) and broadly suppresses immune activation — inhibiting T cell proliferation, downregulating key pro-inflammatory cytokines (IL-2, IFN-γ, TNF-α), and suppressing antigen presentation by dendritic cells.

Alopecia Areata is a CD8+ T-cell-mediated autoimmune disease in which cytotoxic T lymphocytes breach the immune privilege of the hair follicle, causing non-scarring hair loss. The pathogenic cytokine signature (IFN-γ/IL-2-dominant) maps directly onto Dexamethasone's inhibitory targets, making the mechanistic rationale for use in AA biologically coherent and well-grounded.

In clinical practice, Dexamethasone has been deployed specifically in an "oral mini-pulse" (OMP) regimen for AA — typically 5 mg on two consecutive days per week — an intermittent schedule deliberately designed to deliver meaningful immunosuppression while minimising HPA axis suppression and the systemic adverse effects associated with daily corticosteroid use. This positions Dexamethasone as a practical, accessible alternative particularly in settings where JAK inhibitors (baricitinib, ritlecitinib) are unavailable, unaffordable, or contraindicated.

Clinical Trial Evidence

⚠️ Important caveat: All 13 trials retrieved from ClinicalTrials.gov involve Dexamethasone as a supportive or adjunct agent in oncology settings (anti-emesis, myeloma backbone, dexamethasone suppression testing) — none were specifically designed to investigate Dexamethasone for Alopecia Areata. The table below reflects the most informative of these for context; they do not constitute AA-targeted evidence.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02288078	Phase 2	Unknown	74	Prophylactic dexamethasone for fatigue/malaise from regorafenib in metastatic colorectal cancer — steroid used as supportive care only
NCT04343560	N/A	Completed	380	Abnormal steroid metabolome (MACS) and bone strength/body composition — relates to glucocorticoid physiology broadly, not AA
NCT02685826	Phase 1/2	Completed	56	Durvalumab + lenalidomide ± dexamethasone in newly diagnosed multiple myeloma — dexamethasone as combination backbone

No dedicated clinical trials registered on ClinicalTrials.gov specifically for Dexamethasone in Alopecia Areata were identified.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
36086930	2022	RCT	Dermatologic Therapy	Randomized open-label trial comparing dexamethasone OMP vs DPCP contact sensitization in severe pediatric AA (n=30 children <18 y); evaluates efficacy and safety of both modalities in non-progressive severe AA
39042154	2024	Systematic Review + NMA	Archives of Dermatological Research	Network meta-analysis comparing systemic steroids, oral JAK inhibitors, and contact immunotherapy for severe AA (SALT ≥50%); provides head-to-head efficacy and safety ranking across treatment classes
35330017	2022	Prospective Cohort	Journal of Clinical Medicine	Real-world evidence on dexamethasone mini-pulse OMP in AA; assesses treatment effectiveness, adverse event profile, and predictors of successful response in a clinical practice setting
41243342	2025	Case Series + Focused Review	Journal of Dermatological Treatment	Documents durable remission of severe AA with dexamethasone OMP as an alternative when JAK inhibitors are contraindicated or inaccessible; includes a literature review of the corticosteroid pulse approach
36070222	2022	Prospective Cohort	Dermatologic Therapy	Multicentric European study of oral dexamethasone mini-pulse for moderate-to-severe AA, including extensive subtypes (totalis/universalis); evaluates feasibility as a lower-cost alternative to JAK inhibitors
31579982	2019	Prospective Cohort	Dermatologic Therapy	Compares 1-day vs 3-day IV dexamethasone pulse regimens combined with topical clobetasol in severe pediatric AA (n=73, age 1–18 y); >50% scalp regrowth used as primary endpoint
36461625	2023	Review / Dosing Guideline	Pediatric Dermatology	Systematic review of pulse-dose corticosteroid therapy (PDCT) dosing regimens in children with AA; evaluates reported schedules, side effects, and current evidence gaps
26179196	2015	Prospective Cohort (Long-term)	Dermatologic Therapy	Long-term follow-up (median 96 months) of oral dexamethasone pulse + topical corticosteroid in 65 children/adolescents with severe AA (>30% scalp involvement); reports sustained response and relapse rates
16707886	2006	Prospective Comparative Study	Dermatology (Basel)	Head-to-head comparison of three systemic corticosteroid modalities (including dexamethasone) for extensive AA; reports efficacy, relapse rates, and side-effect profiles across regimens
10535249	1999	Prospective Observational	Journal of Dermatology	One of the earliest prospective studies of twice-weekly 5 mg dexamethasone oral pulse in 30 patients with widespread AA; evaluates terminal hair regrowth at ≥12 weeks of treatment

Singapore Market Information

Dexamethasone currently has no registered products with Singapore's HSA (Health Sciences Authority). No license authorization data is available for this analysis. Formal registration would be required before any clinical use pathway can be established.

Safety Considerations

Please refer to the package insert for safety information.

As a synthetic glucocorticoid, Dexamethasone carries well-established class-level risks that are particularly relevant to the intended mini-pulse dosing schedule in AA. These include HPA axis suppression (dose- and duration-dependent), increased susceptibility to infections, osteoporosis and avascular necrosis with prolonged use, and metabolic effects such as hyperglycaemia, weight gain, and dyslipidaemia. Growth suppression is a specific concern in paediatric patients — a population with substantial representation in the existing evidence base. The mini-pulse schedule (2 consecutive days per week) is expressly designed to reduce these risks compared to continuous daily dosing.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic fit between Dexamethasone's glucocorticoid immunosuppression and the CD8+ T-cell-driven pathogenesis of Alopecia Areata is well-established. The evidence base includes 1 published RCT (severe paediatric AA), a 2024 systematic review and network meta-analysis positioning systemic steroids within the treatment landscape, and at least 5 prospective cohort studies specifically using Dexamethasone OMP in AA — collectively supporting its status as a clinically validated off-label option, particularly where JAK inhibitors are inaccessible or contraindicated.

To proceed, the following is needed:

Singapore registration pathway: Dexamethasone has 0 HSA-licensed products on file; a registration or import/supply strategy must be established before clinical use
Package insert and safety data: Full TFDA/HSA-compliant warnings, contraindications, and DDI profile are currently flagged as data gaps — required before formal S1 safety evaluation can be completed
Structured dosing protocol: The mini-pulse regimen (dose, frequency, duration, tapering schedule) should be formalised for the Singapore patient population, with separate considerations for adult and paediatric cases
Safety monitoring plan: HPA axis function, fasting glucose, bone density (for long-term use), and growth parameters (paediatric patients) should be defined as mandatory monitoring items
Positioning relative to JAK inhibitors: A clinical decision framework clarifying when Dexamethasone OMP is preferred over, or used alongside, approved AA therapies (baricitinib, ritlecitinib) in the Singapore formulary context

This report is generated for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.